Monitor the special meeting vote outcome on November 18. If the warrant exercise proposal fails, the company faces litigation risk and loss of ~$8.7M potential proceeds. If the authorized share increase passes, watch for subsequent equity offerings that would further dilute existing shareholders.
Price Chart
Executive Summary
Theriva Biologics is holding a special meeting on November 18, 2026, to seek stockholder approval for three proposals: (1) increasing authorized common shares from 350M to 500M, (2) ratifying the prior approval of issuing up to 16,184,560 shares upon exercise of warrants issued in an October 2025 private placement, and (3) adjourning the meeting if needed. The warrant exercise proposal is being re-submitted due to inconsistent disclosure in the prior proxy statement regarding whether it was a routine or non-routine matter, which has also led to a pending shareholder lawsuit. The authorized share increase is needed to facilitate future equity financings and strategic transactions, but the company has no definitive commitments for such issuances.
Key Facts
- Special meeting on November 18, 2026, to vote on increasing authorized common shares from 350M to 500M.
- Proposal to ratify and confirm prior approval of issuing up to 16,184,560 shares upon exercise of warrants at $0.54 per share, which could yield up to ~$8.7M in gross proceeds.
- A lawsuit, Nejmeh v. Theriva Biologics, Inc., was filed after the 2026 Annual Meeting due to inconsistent disclosure on whether the warrant exercise proposal was routine or non-routine.
- At the 2026 Annual Meeting, the warrant exercise proposal received 3,665,312 FOR, 2,267,592 AGAINST, 123,397 abstentions, and 10,823,826 broker non-votes.
- The company has 45,892,668 shares outstanding as of the record date of October 9, 2026.
- The board unanimously recommends voting FOR all three proposals.
- The company has no definitive commitments for issuing the additional authorized shares if the increase is approved.
- The company has retained D.F. King & Co. to aid in proxy solicitation for fees not exceeding $10,000 plus expenses.
Financial Impact
Potential gross proceeds of up to ~$8.7M from warrant exercise; significant dilution risk from up to 16,184,560 new shares (35% of current outstanding) and potential future dilution from authorized share increase to 500M shares.
Risk Factors
- Potential failure of warrant exercise proposal could lead to additional litigation and loss of ~$8.7M in potential proceeds.
- Authorized share increase enables future dilutive equity issuances without further stockholder approval.
- Pending shareholder lawsuit (Nejmeh v. Theriva) adds legal uncertainty and potential costs.
- Low insider ownership (1.33% by all officers and directors as a group) may indicate limited alignment with minority shareholders.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEF 14A Filing (Primary) | 0001104659-26-117417 |
| Document: 0001104659-26-117417-index-headers.html | 0001104659-26-117417 |
| Document: 0001104659-26-117417-index.html | 0001104659-26-117417 |
| Document: 0001104659-26-117417.txt | 0001104659-26-117417 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 7d ago | DEF 14A | $0.1966 $0.1900 | ▲ +3.36% | ▲ +2.18% | $0.1900 (+3.36%) |
Aug 11, 2026 11w ago | 8-K | $0.2300 $0.2400 | ▲ +4.35% | ▲ +4.10% | $0.1900 (−17.39%) |
Aug 11, 2026 11w ago | Press Release | $0.2300 $0.2400 | ▲ +4.35% | ▲ +4.10% | $0.1900 (−17.39%) |
Aug 4, 2026 12w ago | 8-K | $0.2300 $0.2251 | ▲ +2.13% | ▲ +1.93% | $0.1900 (+17.39%) |
Jul 7, 2026 16w ago | 8-K | $0.2354 $0.2378 | ▲ +1.02% | ▲ +1.33% | $0.1900 (−19.29%) |
Jun 11, 2026 19w ago | Press Release | $0.3070 $0.3038 | ▼ −1.04% | ▼ −1.58% | $0.1900 (−38.11%) |
Apr 17, 2026 27w ago | 8-K | $0.4100 $0.3400 | ▼ −17.07% | ▼ −16.42% | $0.1900 (−53.66%) |
Mar 12, 2026 32w ago | 8-K | $0.1800 $0.1800 | · 0.00% | ▲ +0.60% | $0.1900 (+5.56%) |
Mar 12, 2026 32w ago | Press Release | $0.1800 $0.1800 | · 0.00% | ▲ +0.60% | $0.1900 (+5.56%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers